Literature DB >> 8196624

Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin.

J Cárcamo1, F M Weis, F Ventura, R Wieser, J L Wrana, L Attisano, J Massagué.   

Abstract

Transforming growth factor beta (TGF-beta) and activin bind to receptor complexes that contain two distantly related transmembrane serine/threonine kinases known as receptor types I and II. The type II receptors determine ligand binding specificity, and each interacts with a distinct repertoire of type I receptors. Here we identify a new type I receptor for activin, ActR-IB, whose kinase domain is nearly identical to that of the recently cloned TGF-beta type I receptor, T beta R-I. ActR-IB has the structural and binding properties of a type I receptor: it binds activin only in the presence of an activin type II receptor and forms a heteromeric noncovalent complex with activin type II receptors. In Mv1Lu lung epithelial cells, ActR-IB and T beta R-I signal a common set of growth-inhibitory and transcriptional responses in association with their corresponding ligands and type II receptors. The transcriptional responses include elevated expression of fibronectin and plasminogen activator inhibitor 1. Although T beta R-I and ActR-IB are nearly identical in their kinase domains (90% amino acid sequence identity), their corresponding type II receptor kinase domains are very different from each other (42% amino acid sequence identity). Therefore, signaling of a specific set of responses by TGF-beta and activin correlates with the presence of similar type I kinases in their complex. Indeed, other TGF-beta and activin type I receptors (TSR-I and ActR-I) whose kinase domains significantly diverge from those of T beta R-I and ActR-IB do not substitute as mediators of these growth-inhibitory and extracellular matrix transcriptional responses. Hence, we conclude that the type I receptor subunits are primary specifiers of signals sent by TGF-beta and activin receptor complexes.

Mesh:

Substances:

Year:  1994        PMID: 8196624      PMCID: PMC358748          DOI: 10.1128/mcb.14.6.3810-3821.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  61 in total

1.  Graded changes in dose of a Xenopus activin A homologue elicit stepwise transitions in embryonic cell fate.

Authors:  J B Green; J C Smith
Journal:  Nature       Date:  1990-09-27       Impact factor: 49.962

2.  TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains.

Authors:  J A Pietenpol; R W Stein; E Moran; P Yaciuk; R Schlegel; R M Lyons; M R Pittelkow; K Münger; P M Howley; H L Moses
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  Transforming growth factor-beta inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor.

Authors:  F T Boyd; J Massagué
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

4.  Activin-A, inhibin and transforming growth factor-beta modulate growth of two gonadal cell lines.

Authors:  C Gonzalez-Manchon; W Vale
Journal:  Endocrinology       Date:  1989-09       Impact factor: 4.736

5.  Activins are expressed early in Xenopus embryogenesis and can induce axial mesoderm and anterior structures.

Authors:  G Thomsen; T Woolf; M Whitman; S Sokol; J Vaughan; W Vale; D A Melton
Journal:  Cell       Date:  1990-11-02       Impact factor: 41.582

6.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

7.  Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor.

Authors:  K Tsuchida; L S Mathews; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

8.  Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme.

Authors:  S Andersson; D L Davis; H Dahlbäck; H Jörnvall; D W Russell
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157

9.  Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases.

Authors:  Y Geng; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

10.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta.

Authors:  A Koff; M Ohtsuki; K Polyak; J M Roberts; J Massagué
Journal:  Science       Date:  1993-04-23       Impact factor: 47.728

View more
  83 in total

1.  Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling.

Authors:  H Kaji; L Canaff; J J Lebrun; D Goltzman; G N Hendy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses.

Authors:  Li Yu; Mindy C Hébert; Ying E Zhang
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

Review 3.  Specificity in transforming growth factor-beta signaling pathways.

Authors:  C J Ring; K W Cho
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

4.  A variant of human growth differentiation factor-9 that improves oocyte developmental competence.

Authors:  William A Stocker; Kelly L Walton; Dulama Richani; Karen L Chan; Kiri H Beilby; Bethany J Finger; Mark P Green; Robert B Gilchrist; Craig A Harrison
Journal:  J Biol Chem       Date:  2020-04-29       Impact factor: 5.157

5.  TGF-beta signaling is required for multiple processes during Xenopus tail regeneration.

Authors:  Diana M Ho; Malcolm Whitman
Journal:  Dev Biol       Date:  2008-01-03       Impact factor: 3.582

6.  A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor.

Authors:  Mun Chun Chan; Peter H Nguyen; Brandi N Davis; Nobumichi Ohoka; Hidetoshi Hayashi; Keyong Du; Giorgio Lagna; Akiko Hata
Journal:  Mol Cell Biol       Date:  2007-06-18       Impact factor: 4.272

7.  G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: phenotypes reversed by a tumorigenic mutation.

Authors:  J L Dai; R K Bansal; S E Kern
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Cloning and characterization of a human type II receptor for bone morphogenetic proteins.

Authors:  B L Rosenzweig; T Imamura; T Okadome; G N Cox; H Yamashita; P ten Dijke; C H Heldin; K Miyazono
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 9.  Regulation and Role of TGFβ Signaling Pathway in Aging and Osteoarthritis Joints.

Authors:  Catherine Baugé; Nicolas Girard; Eva Lhuissier; Celine Bazille; Karim Boumediene
Journal:  Aging Dis       Date:  2013-12-17       Impact factor: 6.745

10.  Transforming growth factor-beta type-II receptor signalling: intrinsic/associated casein kinase activity, receptor interactions and functional effects of blocking antibodies.

Authors:  F L Hall; P D Benya; S R Padilla; D Carbonaro-Hall; R Williams; S Buckley; D Warburton
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.